|
**Overview**: OncoPro EGFR ARMS PCR Panel**Introduction**: The OncoPro EGFR ARMS PCR Panel is a diagnostic tool designed to detect EGFR mutations using FFPE tissue. In India, non-small cell lung cancer (NSCLC) is the leading cancer killer (~70,000-80,000 new cases/year), with EGFR mutations present in ~30-50 percent of adenocarcinoma in nonsmokers (higher in women), predicting excellent response to TKIs (gefitinib, osimertinib). High morbidity from under-testing in rural/low-SES lung cancer patients, limited molecular labs, delayed targeted therapy leading to rapid progression or poor survival on chemotherapy alone. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs ARMS-PCR for 7 key EGFR mutations (Exon 19 deletion, L858R, T790M, G719X, S768I, L861Q, Exon 20 insertion) over 1-2 days with high sensitivity/specificity, valuable for first-line TKI selection in advanced NSCLC. This diagnostic falls under genetic cancer screening and targets NSCLC adenocarcinoma patients (especially nonsmokers/young females), addressing accurate detection to guide osimertinib (first-line) or chemotherapy avoidance. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise mutation profiling and improving lung cancer survival. Its FFPE-based approach ensures reliable tumor-specific mutation detection.**Other Names**: EGFR ARMS Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: EGFR ARMS standard in India since 2010s; routine in thoracic oncology.**Purpose**: The test assesses 7 parameters including EGFR Exon 19 Deletion to guide mutation detection, predict TKI response, inform targeted therapy.**Test Parameters**: 1. EGFR Exon 19 Deletion, 2. L858R, 3. T790M, 4. G719X, 5. S768I, 6. L861Q, 7. Exon 20 Insertion.**Pretest Condition**: No fasting required; patients should have confirmed NSCLC biopsy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; testing possible long-term.**Medical History**: Patients should provide details on smoking status, histology, stage.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected mutation including wrong therapy, benefits of profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves sample processing using ARMS-PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor block quality, inadequate tumor content, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Sensitizing mutations (Exon 19 del/L858R) indicate first-line TKI eligibility; T790M resistance, necessitating specialist input.**Specialist Consultation**: Thoracic oncologists should be consulted for management.**Additional Supporting Tests**: PD-L1 IHC, ALK/ROS1 for confirmation.**Test Limitations**: Detects common hotspots; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Lung Cancer Studies India 2023. |
